Prostate Cancer
Conditions
Interventions
Sponsors
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age >= 18 years old; 2.Confirmed as a patient with prostate cancer; 3.Previously received or currently receiving Rezvilutamide treatment; 4.Sign informed consent and voluntarily participate in this study; 5.Male patients whose partners are women with Fertility should be surgically sterilized or agree to use effective methods of contraception during the trial period and within 3 months after the last administration of the study drug;
Exclusion criteria
Exclusion criteria: 1.Patients who are participating in other clinical studies of Rezvilutamide; 2.The researcher judges other situations that are not suitable for inclusion in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| to castration-resistant prostate cancer ( CRPC) time; | — |
Secondary
| Measure | Time frame |
|---|---|
| time to prostate-specific antigen(PSA) onset of response;time to prostate-specific antigen(PSA) progression;Survival and imaging-related endpoints;Relevant clinical improvement metrics;Safety;Pharmaco-Economics;prostate-specific antigen(PSA) response rate; | — |
Countries
China
Contacts
Public ContactXu Danfeng
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Outcome results
None listed